Compare Jabil Inc (JBL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs TG Therapeutics Inc — how do they compare? Jabil Inc trades at $305.62 (market cap $31.35B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Jabil Inc is far larger — about 3.8× TG Therapeutics Inc's market cap, and Jabil Inc pays a 0.11% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and TG Therapeutics Inc for 16 Days on average.
| JBL | TGTX | |
|---|---|---|
Market Cap | $31.35B | $8.16B |
Volume | 1,337,978 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $385.50 | $59.06 |
52-Week Low | $192.49 | $26.94 |
Typical Hold Time | 23 Days | 16 Days |
Enterprise Value | $33.63B | $8.37B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $305.83, up 2.12% with strong Q4 2026 earnings beating estimates at $4.40 EPS versus $4.07 expected. Technical indicators show bearish signals with price near resistance at $304, while fundamentals reveal robust revenue growth to $36.0B projected for 2026 and a high ROE of 74.11%. Recent news highlights AI infrastructure demand driving fiscal 2027 growth targets of 24%.
The outlook is positive with analyst consensus price target of $434.75 implying 42% upside, supported by 14 buy ratings and no sells. Risks include high debt levels and market volatility despite strong earnings, but AI-driven expansion and consistent earnings beats present a compelling growth opportunity for investors.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
